NCT00837902

Genetic Determinants of Response to Beta Blockade

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 154 (actual)
• Sponsor: Vanderbilt University · Academic / Other
• Sex: All
• Age: 18 Years – 40 Years
• Healthy volunteers: Accepted

Summary

The overall goal of this project is to determine the genetic factors contributing to interindividual differences in response to beta-blockade.

Detailed description

The Aim is to define the contribution of genetic variation to the interindividual variability in response to β-blockade. The rationale for the study is as follows: Beta-blockers prevent the activation of β-ARs and thus form the cornerstone of treatment of pathological states such as congestive heart failure and coronary artery disease. Functional polymorphisms in cardiac beta-receptors have been shown to determine response to β-blocker therapy. A physiologic stimulus such as exercise causes sympathetic stimulation and activation of the cardiac β-ARs and genotypic differences in response to β-blockers are magnified under states of heightened sympathetic activity. Thus, in addition to measuring the response to β-blockers at rest, we will also determine the response to β-blockade after sub-maximal exercise on a supine bicycle ergometer. Genetic variations that may alter sensitivity to a beta blocker will be sought.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	Atenolol (β-blocker)	25 mg tablet

Timeline

• Start date: 2009-01-01
• Primary completion: 2012-12-31
• Completion: 2014-12-31
• First posted: 2009-02-06
• Last updated: 2018-11-30
• Results posted: 2018-11-30

Locations

1 site across 1 country: United States